相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Giulia Siravegna et al.
CLINICAL CANCER RESEARCH (2019)
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Klaus Pantel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
Vincent P. Groot et al.
CLINICAL CANCER RESEARCH (2019)
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Raoul Charles Coombes et al.
CLINICAL CANCER RESEARCH (2019)
The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas
Adalgisa Condoluci et al.
CURRENT OPINION IN HEMATOLOGY (2019)
The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance
Grainne M. O'Kane et al.
LUNG CANCER (2019)
A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications
Anna-Lena Volckmar et al.
GENES CHROMOSOMES & CANCER (2018)
Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA
Rui Zhang et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
Zhi Rong Qian et al.
JAMA ONCOLOGY (2018)
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer
S. Kruger et al.
ANNALS OF ONCOLOGY (2018)
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer
Thomas John et al.
LUNG CANCER (2018)
Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
M. Yang et al.
ANNALS OF ONCOLOGY (2018)
Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
Daniel Pietrasz et al.
CLINICAL CANCER RESEARCH (2017)
Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients
He Cheng et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Early detection of pancreatic cancer: Where are we now and where are we going?
Bin Zhou et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Current and Emerging Applications of Droplet Digital PCR in Oncology
Susana Olmedillas-Lopez et al.
MOLECULAR DIAGNOSIS & THERAPY (2017)
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer
Alvin P. Makohon-Moore et al.
NATURE GENETICS (2017)
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
Rui-hua Xu et al.
NATURE MATERIALS (2017)
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer
Hideyuki Hayashi et al.
PANCREAS (2017)
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
Joshua D. Cohen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case
Valentina Appierto et al.
SEMINARS IN CANCER BIOLOGY (2017)
Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma
Ting Xu et al.
THERANOSTICS (2017)
Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer
Nikolas von Bubnoff
ONCOLOGY RESEARCH AND TREATMENT (2017)
Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis
A. Creemers et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)
The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review
Ian A. Cree et al.
BMC CANCER (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients
Joost H. van Ginkel et al.
BMC CANCER (2017)
Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma
Toshiaki Komo et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer
Francesca Riva et al.
MOLECULAR ONCOLOGY (2016)
Coming of age: ten years of next-generation sequencing technologies
Sara Goodwin et al.
NATURE REVIEWS GENETICS (2016)
Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer
Hideaki Kinugasa et al.
CANCER (2015)
Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility
Michail Ignatiadis et al.
CLINICAL CANCER RESEARCH (2015)
GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma
Marcus C. Tan et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Sonia A. Melo et al.
NATURE (2015)
Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study
Ippei Matsumoto et al.
PANCREATOLOGY (2015)
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Mark Sausen et al.
NATURE COMMUNICATIONS (2015)
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
Francois-Clement Bidard et al.
LANCET ONCOLOGY (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
US Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations
Sean Khozin et al.
ONCOLOGIST (2014)
KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance
Umberto Miglio et al.
PATHOLOGY RESEARCH AND PRACTICE (2014)
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Jianjun Zhang et al.
SCIENCE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
Javier Sastre et al.
ONCOLOGIST (2012)
Early Recurrence of Pancreatic Cancer after Resection and During Adjuvant Chemotherapy
Richard Fischer et al.
SAUDI JOURNAL OF GASTROENTEROLOGY (2012)
Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development
Jian Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
分享论文
